Features | Partner Sites | Information | LinkXpress
Sign In
JIB
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING

Gene “Toggle” Regenerates Injured Heart Cells

By BiotechDaily International staff writers
Posted on 08 May 2012
For the first time, researchers have transformed scar tissue that grows after a heart attack into regenerated heart muscle using microRNAs, according to new lab animal research. If validated in human studies, this finding could help prevent heart failure after a heart attack and applied to other types of tissue regeneration.

The study’s findings were reported online before print April 26, 2012, in Circulation Research, an American Heart Association journal. After a heart attack, heart muscle does not effortlessly regenerate and it accumulates scar tissue, comprised of cells called fibroblasts--increasing risk for heart failure.

“Researchers have tried various approaches, including the use of stem cells, to regenerate damaged heart muscle tissue,” said Victor J. Dzau, MD, the study’s senior author and a professor of medicine at Duke University Medical Center (Durham, NC, USA). “This is the first study to use microRNA, which are small molecules that control gene expression, to reprogram fibroblasts into heart muscle cells. We have not only shown evidence of this tissue regeneration in cell cultures, but also in mice.”

Using microRNA is simpler than many other tissue-regenerating approaches, according to Dr. Dzau, who is also chancellor for health affairs at Duke University. For example, stem cells are not easy to work with and have ethical issues surrounding their use, he noted. “This research represents a major advance in regenerative medicine overcoming the difficulties encountered with stem cells, and may be applied to other conditions of tissue damage such as stroke and spinal cord injury.”

Dr. Dzau’s team identified a combination of three microRNA types that convert fibroblasts to muscle cells. In the next phase of research, the researchers will assess whether microRNAs repair damaged hearts in larger animals and improve heart function. If those studies prove safe and effective, they will begin human studies. “If everything comes to fruition, I think we will see this as a therapy in the next decade,” Dr. Dzau said. “Conceivably, we’ll use it to regenerate hearts damaged by heart attacks, avoiding heart failure and saving lives.”

Related Links:

Duke University Medical Center




comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: Differences in the structure of a small lung artery (top row) and heart cross section (lower row) of rodents without disease (far left column); with pulmonary hypertension (middle) and a diseased rodent treated with the HDL peptide (right). Note the much narrowed lung artery, and thick walls and larger chamber of the heart in the diseased animal and improvements with 4F peptide treatment (Photo courtesy of UCLA - University of California, Los Angeles).

Apolipoprotein A-1 Mimetic Peptide Reverses Pulmonary Hypertension in Rodent Models

A small peptide that mimics the activity of apolipoprotein A-1 (apo A-1), the main protein component of the high density lipoproteins (HDL), counteracted the effects of oxidized lipids and alleviated symptoms... Read more

Drug Discovery

view channel
Image: The five stages of biofilm development: (1) Initial attachment, (2) Irreversible attachment, (3) Maturation I, (4) Maturation II, and (5) Dispersion. Each stage of development in the diagram is paired with a photomicrograph of a developing P. aeruginosa biofilm. All photomicrographs are shown to same scale (Photo courtesy of Wikimedia Commons).

Ionic Liquids Disperse Bacterial Biofilms and Increase Antibiotic Susceptibility

The ionic liquid choline-geranate was shown to effectively eliminate the protective biofilm generated by bacteria such as Salmonella enterica and Pseudomonas aeruginosa and to significantly increase the... Read more

Lab Technologies

view channel

Important Immune Cell Regulators’ Response Identified

A new strategy could help accelerate laboratory research and the development of potential therapeutics, including vaccines. The technology may also be used to identify the genes that underlie tumor cell development. There are approximately 40,000 genes in each of the body’s cells, but functions for only approximately... Read more

Business

view channel

Partnership Established to Decode Bowel Disease

23andMe (Mountain View, CA,USA), a personal genetics company, is collaborating with Pfizer, Inc. (New York, NY, USA), in which the companies will seek to enroll 10,000 people with inflammatory bowel disease (IBD) in a research project designed to explore the genetic factors associated with the onset, progression, severity,... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.